Takeda Pharmaceutical Co Ltd (NYSE:TAK) was the recipient of some unusual options trading on Thursday. Stock traders purchased 5,006 put options on the stock. This represents an increase of approximately 6,080% compared to the typical daily volume of 81 put options.
Several research firms have issued reports on TAK. Zacks Investment Research upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research note on Tuesday, April 30th. ValuEngine lowered Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Goldman Sachs Group reiterated a “buy” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, March 19th.
Shares of NYSE TAK traded up $0.15 during trading hours on Friday, reaching $17.53. 103,486 shares of the stock were exchanged, compared to its average volume of 2,650,255. The firm has a market cap of $28.17 billion, a P/E ratio of 16.38, a price-to-earnings-growth ratio of 62.15 and a beta of 0.66. The company has a current ratio of 1.22, a quick ratio of 2.81 and a debt-to-equity ratio of 0.92. Takeda Pharmaceutical has a 52 week low of $15.50 and a 52 week high of $21.95.
Several hedge funds and other institutional investors have recently made changes to their positions in TAK. First Hawaiian Bank bought a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $35,000. Dubuque Bank & Trust Co. bought a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $41,000. Dumont & Blake Investment Advisors LLC bought a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $230,000. Neville Rodie & Shaw Inc. bought a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $475,000. Finally, Contravisory Investment Management Inc. bought a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $28,000. Institutional investors own 4.42% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Investors Buy Large Volume of Put Options on Takeda Pharmaceutical (TAK)” was published by Equities Focus and is the property of of Equities Focus. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.equitiesfocus.com/2019/05/17/investors-buy-large-volume-of-put-options-on-takeda-pharmaceutical-tak.html.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
See Also: What is a trade deficit?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.